Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$10.96K$10.96K+40.7% vs Q3 2021 Net Income-$603.36K-$603.36KN/M vs Q3 2021 EPS Diluted$0.00$0.00N/M vs Q3 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$123,861N/M Margins · derivedGross margin63.3%+3.1 pt vs Q3 2021
Operating margin-4532.6%+4353.8 pt vs Q3 2021
Net margin-5505.1%+14054.2 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 21, 2022 · 52 d after period end